拜耳将收购Perfuse Therapeutics以补充眼科药物研发管线-动脉网

Bayer to acquire Perfuse Therapeutics to complement ophthalmology pipeline

拜耳等信源发布 2026-05-06 14:32



可切换为仅中文







May

五月

2026

08:30 AM

Europe/Amsterdam

欧洲/阿姆斯特丹

Bayer to acquire Perfuse Therapeutics to complement ophthalmology pipeline

拜耳将收购Perfuse Therapeutics以补充眼科药物管线

Not intended for UK Media

不适用于英国媒体

Summary

摘要

Perfuse Therapeutics’ investigational lead program shows potential to become one of the first disease-modifying treatments for both Glaucoma and Diabetic Retinopathy (DR) / High unmet medical need of patients with Glaucoma affecting up to 80 million people

Perfuse Therapeutics的实验性主导项目显示出有可能成为青光眼和糖尿病视网膜病变（DR）的首批疾病修饰治疗之一/青光眼患者未满足的高医疗需求，影响多达8000万人

and Diabetic Retinopathy affecting around 146 million

糖尿病视网膜病变影响约1.46亿人

worldwide / Acquisition complements Bayer’s pharmaceutical pipeline and strategically fits with Bayer’s footprint and expertise in ophthalmology

全球范围内/收购补充了拜耳的制药管线，并战略性地契合了拜耳在眼科领域的布局和专业知识。

Berlin, Germany and San Francisco, California USA, May 6, 2026

德国柏林，美国加利福尼亚州旧金山，2026年5月6日

–

Bayer and Perfuse Therapeutics Inc. today announced an agreement under which Bayer will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into the treatment of ischemia-induced ocular diseases. With this acquisition, Bayer will hold the full rights pertaining to PER-001, a small molecule endothelin receptor antagonist currently in Phase II clinical development for the treatment of Glaucoma and Diabetic Retinopathy (DR)..

拜耳和Perfuse Therapeutics公司今天宣布了一项协议，根据该协议，拜耳将全面收购致力于缺血性眼病治疗的转化研究的生物制药公司Perfuse Therapeutics。通过这次收购，拜耳将持有目前处于二期临床开发阶段用于治疗青光眼和糖尿病视网膜病变（DR）的小分子内皮素受体拮抗剂PER-001的全部权利。

This represents one of the first potential treatments for Glaucoma and DR being studied for its ability to improve the visual field for Glaucoma patients and to improve contrast sensitivity and reduce ischemia in DR patients.

这代表了首批潜在的青光眼和糖尿病视网膜病变治疗方法之一，该方法正被研究用于提高青光眼患者的视野，改善糖尿病视网膜病变患者的对比敏感度并减少缺血。

“We are excited by the work of the team at Perfuse Therapeutics and encouraged by the potential of PER-001,” said Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer Pharmaceuticals. “With this acquisition, we are complementing our expertise in ophthalmology and our pipeline, reinforcing our commitment to developing urgently needed therapies for patients.” .

“我们对Perfuse Therapeutics团队的工作感到兴奋，并对PER-001的潜力感到鼓舞，”拜耳制药业务发展与许可负责人尤尔根·埃克哈特医学博士表示。“通过此次收购，我们正在补充我们在眼科领域的专业知识和研发管线，进一步巩固我们为患者开发亟需疗法的承诺。”

“I’m incredibly proud of what the Perfuse team has accomplished and deeply thankful to all our investors and collaborators,' said Sevgi Gurkan, MD, Founder and CEO of Perfuse Therapeutics, Inc. 'Bayer’s vision aligns closely with ours, and they have the scale and global resources to unlock the full potential of PER-001 to change the trajectory of human blindness.

“我为Perfuse团队取得的成就感到无比自豪，并对所有投资者和合作伙伴深表感谢，”Perfuse Therapeutics公司创始人兼首席执行官Sevgi Gurkan医学博士表示，“拜耳的愿景与我们高度契合，他们拥有规模和全球资源，能够充分释放PER-001的潜力，改变人类失明的发展轨迹。”

We are very excited to see our mission continue with even greater momentum.”.

我们非常兴奋地看到我们的使命以更大的动力继续前进。”

Glaucoma is a progressive optic neuropathy that causes the loss of retinal ganglion cells, resulting in loss of visual fields. It is the leading cause of irreversible vision loss

青光眼是一种进行性的视神经病变，会导致视网膜神经节细胞的丧失，从而引起视野的缺失。它是不可逆性视力丧失的主要原因。

affecting ~76-80 million people worldwide (2020) and is projected to affect ~112 million people by 2040 due to population aging.

影响全球约7600万至8000万人（2020年），并预计到2040年由于人口老龄化将影响约1.12亿人。

Despite its prevalence, there are no approved treatments today, preventing disease progression and blindness independently from the saturated approach of lowering intraocular pressure. There is a high unmet medical need for neuroprotective treatments for patients with Glaucoma.

尽管其普遍性，目前尚无获批的治疗方法，可以独立于降低眼压的饱和方法之外阻止疾病进展和失明。青光眼患者对神经保护性治疗存在高度未满足的医疗需求。

Diabetic Retinopathy (DR) is a microvascular complication of diabetes that damages retinal capillaries, causing ischemia, leakage, and neovascularization affecting about 146 million people globally today. This includes about 25 percent of adults with diabetes and is projected to increase to 160 million people by 2045.

糖尿病视网膜病变（DR）是糖尿病的一种微血管并发症，会损害视网膜毛细血管，导致缺血、渗漏和新生血管形成，目前全球约有1.46亿人受到影响。这包括大约25%的成年糖尿病患者，并预计到2045年将增加至1.6亿人。

Currently, 25 million people have vision‑threatening DR and 1.3 million people are blind..

目前，有2500万人患有威胁视力的糖尿病视网膜病变，其中130万人失明。

Under the terms of the agreement, the transaction carries a total potential value of up to USD 2.45 billion, comprising a USD 300 million upfront payment and additional development, regulatory, and commercial milestone payments based on success criteria.

根据协议条款，该交易的总潜在价值高达 24.5 亿美元，其中包括 3 亿美元的首付款，以及基于成功标准的额外开发、监管和商业里程碑付款。

For Bayer, BofA Securities is acting as exclusive financial advisor and Baker McKenzie is acting as legal counsel. For Perfuse, Centerview Partners LLC is acting as exclusive financial advisor and Goodwin Procter LLP is acting as legal counsel.

对于拜耳，美国银行证券担任独家财务顾问，贝克·麦坚时律师事务所担任法律顾问。对于Perfuse，Centerview Partners LLC担任独家财务顾问，Goodwin Procter LLP担任法律顾问。

The acquisition is subject to and will become effective after receiving the necessary antitrust clearances and Perfuse stockholder approvals.

收购需在获得必要的反垄断许可和Perfuse股东批准后方可生效。

About PER-001

关于 PER-001

PER-001 is an investigational small molecule endothelin receptor antagonist being developed for the treatment of ophthalmic diseases. Endothelin is the most potent vasoconstrictor in the human body and is upregulated in glaucoma, diabetic retinopathy, age-related macular degeneration and retinal vein occlusion.

PER-001 是一种正在开发中的研究性小分子内皮素受体拮抗剂，用于治疗眼科疾病。内皮素是人体中最有效的血管收缩剂，并在青光眼、糖尿病视网膜病变、年龄相关性黄斑变性和视网膜静脉阻塞中上调。

Endothelin is involved in inflammation and cell death through its receptors expressed in retinal vascular and neuroretinal cells. The PER-001 intravitreal implant is a bio-erodible implant administered into the vitreous cavity of the eye using a single-use, 25-gauge applicator and designed to provide a sustained release of PER-001, allowing for a convenient dosing regimen..

内皮素通过其在视网膜血管和神经视网膜细胞中表达的受体参与炎症和细胞死亡。PER-001 玻璃体内植入物是一种生物可降解植入物，使用一次性 25 号规格施药器将其注入眼球的玻璃体腔，旨在提供 PER-001 的持续释放，从而实现便捷的给药方案。

About Perfuse Therapeutics

关于Perfuse Therapeutics

Perfuse Therapeutics is a biopharmaceutical company pioneering transformational research into the treatment of ischemia-induced ocular diseases. Enabled by its proprietary sustained-release drug delivery platform, the company is advancing its lead asset PER-001 for global leading causes of blindness.

Perfuse Therapeutics是一家生物制药公司，率先开展针对缺血性眼病治疗的变革性研究。依托其专有的缓释药物递送平台，该公司正在推进其主要资产PER-001，用于全球致盲的主要原因。

Headquartered in South San Francisco, Calif., and with R&D facilities in Durham, N.C., Perfuse Therapeutics has established a strong team committed to advancing disease-modifying therapies to patients with ocular disease around the world. For more information, visit www.perfusetherapeutics.com and LinkedIn..

总部位于加利福尼亚州南旧金山，并在北卡罗来纳州达勒姆设有研发设施，Perfuse Therapeutics 拥有一支强大的团队，致力于为全球眼部疾病患者推进疾病修饰疗法。欲了解更多信息，请访问 www.perfusetherapeutics.com 和 LinkedIn。

About Bayer

关于拜耳

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population.

拜耳是一家在医疗保健和营养等生命科学领域具有核心竞争力的全球性企业。秉承“人人健康，无饥饿”的使命，公司的产品和服务旨在帮助人类和地球繁荣发展，支持应对不断增长和老龄化的全球人口所带来的重大挑战。

Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros.

拜耳致力于推动可持续发展，并通过其业务产生积极影响。同时，集团旨在通过创新和增长提高盈利能力并创造价值。拜耳品牌在全球范围内代表信任、可靠性和质量。在2025财年，该集团拥有约88,000名员工，销售额达456亿欧元。

R&D expenses amounted to 5.8 billion euros. For more information, go to .

研发费用总计达58亿欧元。欲了解更多信息，请访问。

www.bayer.com

。

Find more information at

更多信息请访问

https://pharma.bayer.com

在Facebook上关注我们：

http://www.facebook.com/bayer

Forward-Looking Statements

前瞻性声明

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.

本发布可能包含基于拜耳管理层当前假设和预测的前瞻性声明。各种已知和未知的风险、不确定性和其他因素可能导致公司的实际未来结果、财务状况、发展或业绩与这里给出的估计存在重大差异。

These factors include those discussed in Bayer’s public reports which are available on the Bayer website at .

这些因素包括拜耳公开报告中讨论的因素，该报告可在拜耳网站上查阅。

www.bayer.com

. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

公司不承担任何更新这些前瞻性声明或使其符合未来事件或发展的责任。

Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires.

拜耳集团是一家在全球范围内拥有运营子公司的控股公司。本文中提到的“拜耳”或“该公司”可能根据上下文需要指代一个或多个子公司。

Vision Loss Expert Group of the Global Burden of Disease, 2024, Eye

全球疾病负担视力丧失专家组，2024，眼科

² Sarkis et al., 2025, Frontiers in Med

² 萨尔基斯等，2025年，《医学前沿》

³ WHO, 2019, World report on vision Executive Summary

³ 世界卫生组织，2019年，《世界视力报告》执行摘要

Bayer Global Media Contact:

拜耳全球媒体联系人：

Lisa Varrelmann,

丽莎·瓦勒尔曼，

phone +49 1746466492